APAC's Venture Class of 2021 Did Not Fail. It Stopped Moving.

Aug 30

3 min read

What's New

Most of the companies funded at the peak of APAC's venture boom are still alive, and that turns out to be the least informative fact about them. Of the 24,602 companies that raised in 2020 or 2021, 82.8% remain active and privately held and only 7.5% are recorded as bankrupt or out of business, according to PitchBook's analyst note Five Years After APAC's VC Boom, What Has Become of Its Companies?. Survival has not translated into progression. Only 46.8% of the cohort raised again after 2021, 20.4% raised twice or more, and just 25.6% advanced to a later venture stage. Measured against the two preceding cohorts, the boom class failed less often and progressed less often, which means the market reset arrived as stalling rather than as attrition.

Why It Matters

A venture cohort that neither dies nor advances is the hardest kind of portfolio to value and the hardest to exit. For LPs, it converts a mark to market question into a duration question, because capital sits in companies that are technically fine and structurally stuck. For GPs, it means the reserve strategy built for a two year follow on cycle is now funding positions that have not moved in four. For technology platforms, the monitoring problem shifts from tracking events to tracking their absence, which no system designed around deal flow does well.

Big Picture Drivers

Abundant capital bought time, not progress: Companies funded in 2020 and 2021 raised into a peak market and many secured a quick follow on round. That cushion delayed the reckoning rather than removing it.
The failure rate fell for the wrong reason: Attrition dropped from 15.7% in the 2016 to 2017 cohort to 10.8% and then 7.5%. Companies are staying alive on old capital instead of clearing the market.
Exits closed before failures did: The share reaching any exit fell across all three cohorts, from 14.9% to 13.2% to 9.7%. The liquidity door narrowed faster than the funding door.
Stage determines everything: Among active companies still marked at pre seed or seed, 87.7% have not recorded a financing in at least four years, against 18% at venture growth. The backlog is concentrated at the bottom of the stack.
Capital size offers no protection: CoinSwitch, Ajaib Teknologi Indonesia and v2food each raised more than $100 million and are still classified as early stage with no recorded round since 2021.
Consumer took the damage: B2C companies raised again at 37.8% against 56.4% for healthcare, and 47.6% of them sit active with no financing since 2021.

By The Numbers

24,602 companies, in the 2020 to 2021 cohort, the largest venture class APAC has produced.
$233.2 billion across 19,049 deals, at the 2021 peak, the reference point every subsequent year is measured against.
40.3% active with no subsequent financing, up from 32.5% for the 2016 to 2017 cohort, the single number that defines the backlog.
1.6 years median to the next round, for those that did raise, actually faster than the 1.7 to 1.9 years of earlier cohorts.
20.4% raised twice or more, against 25.6% and 24.4% for the two prior cohorts, showing where the cycle broke.
10.5% versus 3.9% out of business, for B2C against healthcare, a spread that maps directly onto business model rather than geography.

Key Trends to Watch

The seed backlog forces a pricing event: Nearly nine in ten stalled seed companies will need either a round at a reset valuation or an orderly wind down. Both create marks that funds have so far avoided taking.
Secondaries move down market in Asia: A cohort this large with this little exit activity is the raw material for LP led and GP led secondary supply, which the region has barely developed.
Healthcare separates from the index: Structural demand and longer development cycles keep private rounds flowing, so sector dispersion inside APAC venture will widen rather than converge.
Acquirers set the clearing price: With IPOs thin, the 5.7% acquisition rate becomes the mechanism that resolves the backlog, and strategic buyers will price against four year old marks.
Fund life extensions become routine: Vehicles from 2020 and 2021 will hit their stated terms with most value unrealised, pushing extension requests and continuation structures into venture where they remain unusual.

The Wrap

The useful contribution here is a definition. Survival and progression are different outcomes, and the industry has been reporting the first while implying the second. A cohort that is 82.8% alive and 25.6% progressed is not a healthy market, it is a market that has postponed its resolution. For technology providers, the product implication is inversion: the valuable signal is no longer the event, it is the elapsed time since the last one, and almost no portfolio monitoring system is built to surface silence as a risk indicator.